RSC Medicinal ChemistryBiophysicsPeer-reviewed journal article
Discovery of a CHI3L1-Targeted Small Molecule Modulating Neuroinflammation in Alzheimers Disease via DNA-Encoded Library (DEL) Screening
Baljit KauriD, Longfei ZhangiD, Hossam NadaiD, Laura Calvo‐BarreiroiD, Moustafa Tarek GabriD
Abstract
Chitinase-3-like protein 1 (CHI3L1, also known as YKL-40) has emerged as a central effector of astrocyte-mediated neuroinflammation and a promising biomarker for Alzheimers disease (AD). However, small molecule CHI3L1 inhibitors that modulate neuroinflammation are limited. Here, we report the discovery of a CHI3L1-targeted small molecule, DEL-C1, identified through DNA-encoded library (DEL) screening and validated using orthogonal biophysical, computational, and cellular approaches. DEL-C1 demonstrated direct CHI3L1 binding in microscale thermophoresis (MST) and surface plasmon resonance (SPR) assays, with reversible and concentration-dependent association. Molecular docking and 100-ns molecular dynamics simulations revealed a stable binding mode within the CHI3L1 substrate groove, anchored by Tyr206 and flanked by Trp99 and Trp352, supporting a thermodynamically favorable interaction. In vitro ADME profiling indicated a balanced physicochemical profile, permeability, and metabolic stability, consistent with CNS drug-like properties. Functionally, DEL-C1 reversed CHI3L1-induced astrocyte dysfunction by restoring A{beta} uptake, lysosomal acidification, and proteolytic activity, while reducing CHI3L1 and IL-6 secretion. DEL-C1 also suppressed CHI3L1-driven NF-{kappa}B transcriptional activation, highlighting its anti-inflammatory potential. Collectively, this study establishes DEL-C1 as a promising small molecule modulator of CHI3L1 and a chemical tool to interrogate astrocyte-driven neuroinflammation in AD.
- organism: human
- assay: proteomics
- research focus: drug response / drug discovery
- approach: deep learning
- approach: statistical model
- Citations
- 2
- FWCI
- 9.14
- Field percentile
- top 4%
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Discovery of a brain-penetrant CHI3L1 inhibitor as an oral modulator of neuroinflammation in Alzheimers disease
Saurabh Upadhyay, Longfei Zhang, … Moustafa Gabr·bioRxiv·Oct 21, 2026
- Restoring Amyloid Clearance via Astrocytes: Z17 Is a Selective Inhibitor of CHI3L1 in Alzheimers Disease
Hossam Nada, Longfei Zhang, … Moustafa Tarek Gabr·bioRxiv·Dec 10, 2025
- Targeting CHI3L1 in Alzheimers Disease: Optimization of G721-0282 and Functional Evaluation in Astrocyte Models
Baljit Kaur, Hossam Nada, … Moustafa Tarek Gabr·bioRxiv·Jan 13, 2026
- Discovery of ILT3 (LILRB4) Small Molecule Inhibitors by Affinity Se-lection-Mass Spectrometry Reveals Druggability of a Neuroimmune Checkpoint in Alzheimers Disease
Somaya A. Abdel‐Rahman, N. Arul Murugan, Moustafa Tarek Gabr·European Journal of Medicinal Chemistry ReportsPeer-reviewed·Oct 1, 2026
- From DNA-Encoded Library (DEL) Screening to In Vivo Validation: LILRB4 (ILT3)-Targeted Small Molecules Reprograms Myeloid Immune Suppression
Somaya A. Abdel‐Rahman, Moustafa Tarek Gabr·Biomedicine & PharmacotherapyPeer-reviewed·Jul 6, 2026
- High-Throughput CETSA Identifies Small Molecule Modulators of ILT3 (LILRB4) with Functional Activity in Human iPSC-Derived Microglia for Alzheimers Disease
Somaya A. Abdel‐Rahman, Moustafa Tarek Gabr·ACS Medicinal Chemistry LettersPeer-reviewed·Jun 18, 2026